To explore the mechanism that mediates the antitumor effect of BI-2493 and BI-2865, we selected the control HEK293T cell line and the KRAS WT–amplified cancer cell lines SNU-245 (cholangiocarcinoma, CN = 28.1), MKN1 (gastric, CN = 12.7), and DMS 53 (NSCLC, CN = 9.6). The gene discussed is KRAS; the disease is cholangiocarcinoma.